1214348-81-8

Basic information

• Product Name: 2-bromo-4-chloro-1-(difluoromethoxy)benzene
• Synonyms: 2-bromo-4-chloro-1-(difluoromethoxy)benzene
• CAS NO: 1214348-81-8
• Molecular Formula: C₇H₄BrClF₂O
• Molecular Weight: 257.4598664
• Mol File: 1214348-81-8.mol
• Article Data: 15

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 2-bromo-4-chloro-1-(difluoromethoxy)benzene(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-4-chloro-1-(difluoromethoxy)benzene(1214348-81-8)
• EPA Substance Registry System: 2-bromo-4-chloro-1-(difluoromethoxy)benzene(1214348-81-8)

Safety Data

• Hazardous Substances Data: 1214348-81-8(Hazardous Substances Data)

Usage

General Description

2-bromo-4-chloro-1-(difluoromethoxy)benzene is a synthetic, halogenated organic compound consisting of a benzene ring as the core structure, with diverse halogen atom attachments. These attachments include a bromine (Br) atom at the second carbon, a chlorine (Cl) atom at the fourth carbon, and a difluoromethoxy group (-OCHF2) at the first carbon. This chemical compound is often used in laboratory settings for different chemical reactions, specifically in organic synthesis due to its reactivity and structural properties. The exact properties (like melting point, boiling point, molecular weight etc.) and hazards of this compound may vary under different conditions. Like many halogenated organic compounds, it needs to be handled with caution due to its potential toxicity and environmental impact.

InChI:InChI=1S/C7H4BrClF2O/c8-5-3-4(9)1-2-6(5)12-7(10)11/h1-3,7H

Upstream product

• 695-96-5 2-bromo-4-chlorophenol 
• 115262-01-6 [bromo(difluoro)methyl]-trimethyl-silane 
• 65094-22-6 diethyl (bromodifluoromethyl)phosphonate 
• 354-08-5 bromodifluoroacetic acid 
• 1885-46-7 trifluoromethanesulfonic acid difluoromethyl ether 
• 1895-39-2 sodium chlorodifluoroacetate 

Relevant articles and documents

Heterocyclic compound and application thereof

The invention discloses a heterocyclic compound and application thereof. The invention provides a heterocyclic compound shown as a formula I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof. The compound can be used as an FXIa inhibit

Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use

The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling

Disruption of interleukin-13 (IL-13) signaling with large molecule antibody therapies has shown promise in diseases of allergic inflammation. Given that IL-13 recruits several members of the Janus Kinase family (JAK1, JAK2, and TYK2) to its receptor complex, JAK inhibition may offer an alternate small molecule approach to disrupting IL-13 signaling. Herein we demonstrate that JAK1 is likely the isoform most important to IL-13 signaling. Structure-based design was then used to improve the JAK1 potency of a series of previously reported JAK2 inhibitors. The ability to impede IL-13 signaling was thereby significantly improved, with the best compounds exhibiting single digit nM IC50’s in cell-based assays dependent upon IL-13 signaling. Appropriate substitution was further found to influence inhibition of a key off-target, LRRK2. Finally, the most potent compounds were found to be metabolically labile, which makes them ideal scaffolds for further development as topical agents for IL-13 mediated diseases of the lungs and skin (for example asthma and atopic dermatitis, respectively).